A retrospective study evaluating the efficacy and safety of apatinib for advanced alveolar soft part sarcoma
Latest Information Update: 28 Jun 2018
Price :
$35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Alveolar soft part sarcoma
- Focus Adverse reactions; Therapeutic Use
- 28 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology